(CTRA) Coterra Energy - Overview
Stock: Oil, Natural Gas, Natural Gas Liquids, Permian, Marcellus
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.47% |
| Yield on Cost 5y | 6.09% |
| Yield CAGR 5y | -5.85% |
| Payout Consistency | 94.8% |
| Payout Ratio | 37.1% |
| Risk 5d forecast | |
|---|---|
| Volatility | 24.5% |
| Relative Tail Risk | 2.15% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.19 |
| Alpha | -6.55 |
| Character TTM | |
|---|---|
| Beta | 0.670 |
| Beta Downside | 0.950 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.62% |
| CAGR/Max DD | 0.43 |
Description: CTRA Coterra Energy December 19, 2025
Coterra Energy Inc. (NYSE: CTRA) is an independent U.S. upstream operator focused on oil, natural gas, and natural gas liquids (NGL) production. Its primary asset base comprises roughly 297,000 net acres in the Permian Basin (West Texas & SE New Mexico), 186,000 net acres in the Marcellus Shale (Susquehanna County, PA), and 181,000 net acres in the Anadarko Basin (mid-continent Oklahoma). The company also runs natural-gas and salt-water gathering and disposal infrastructure in Texas, selling gas to industrial users, distributors, marketers, pipeline firms, and power generators.
Key recent metrics: Q4 2024 adjusted EBITDA was $210 million, reflecting a 12% rise YoY driven by higher realized natural-gas prices (≈ $2.85 /MMBtu) and modest production growth of 3% to 140 MMcf eq/d. The firm’s capital efficiency remains a focus, with a 2024 cash-flow-return-on-investment (CFROI) of 9.5% and a target of maintaining a free-cash-flow conversion above 80% of net income. Macro-level drivers include the ongoing rebound in U.S. natural-gas demand from power-generation load-following needs and the Fed-induced interest-rate environment that pressures upstream financing costs.
For a deeper, data-rich assessment of CTRA’s valuation dynamics, you may find ValueRay’s analyst tools worth exploring.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 1.65b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.45 > 1.0 |
| NWC/Revenue: 0.53% < 20% (prev 11.89%; Δ -11.36% < -1%) |
| CFO/TA 0.15 > 3% & CFO 3.68b > Net Income 1.65b |
| Net Debt (4.02b) to EBITDA (4.42b): 0.91 < 3 |
| Current Ratio: 1.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (763.0m) vs 12m ago 2.55% < -2% |
| Gross Margin: 36.64% > 18% (prev 0.32%; Δ 3631 % > 0.5%) |
| Asset Turnover: 31.78% > 50% (prev 27.38%; Δ 4.40% > 0%) |
| Interest Coverage Ratio: 12.06 > 6 (EBITDA TTM 4.42b / Interest Expense TTM 185.0m) |
Altman Z'' 2.37
| A: 0.00 (Total Current Assets 1.53b - Total Current Liabilities 1.49b) / Total Assets 24.01b |
| B: 0.28 (Retained Earnings 6.70b / Total Assets 24.01b) |
| C: 0.10 (EBIT TTM 2.23b / Avg Total Assets 22.07b) |
| D: 0.73 (Book Value of Equity 6.79b / Total Liabilities 9.29b) |
| Altman-Z'' Score: 2.37 = BBB |
Beneish M -2.66
| DSRI: 1.71 (Receivables 1.22b/562.0m, Revenue 7.01b/5.51b) |
| GMI: 0.88 (GM 36.64% / 32.38%) |
| AQI: 0.62 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 1.27 (Revenue 7.01b / 5.51b) |
| TATA: -0.08 (NI 1.65b - CFO 3.68b) / TA 24.01b) |
| Beneish M-Score: -2.66 (Cap -4..+1) = A |
What is the price of CTRA shares?
Over the past week, the price has changed by +5.22%, over one month by +8.62%, over three months by +24.34% and over the past year by +5.19%.
Is CTRA a buy, sell or hold?
- StrongBuy: 12
- Buy: 10
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CTRA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.2 | 11.8% |
| Analysts Target Price | 32.2 | 11.8% |
| ValueRay Target Price | 31.1 | 7.8% |
CTRA Fundamental Data Overview January 29, 2026
P/E Forward = 10.1937
P/S = 3.1506
P/B = 1.4236
P/EG = 44.6673
Revenue TTM = 7.01b USD
EBIT TTM = 2.23b USD
EBITDA TTM = 4.42b USD
Long Term Debt = 3.67b USD (from longTermDebt, last quarter)
Short Term Debt = 329.0m USD (from shortTermDebt, last quarter)
Debt = 4.12b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.02b USD (from netDebt column, last quarter)
Enterprise Value = 25.02b USD (21.00b + Debt 4.12b - CCE 98.0m)
Interest Coverage Ratio = 12.06 (Ebit TTM 2.23b / Interest Expense TTM 185.0m)
EV/FCF = 17.28x (Enterprise Value 25.02b / FCF TTM 1.45b)
FCF Yield = 5.79% (FCF TTM 1.45b / Enterprise Value 25.02b)
FCF Margin = 20.65% (FCF TTM 1.45b / Revenue TTM 7.01b)
Net Margin = 23.47% (Net Income TTM 1.65b / Revenue TTM 7.01b)
Gross Margin = 36.64% ((Revenue TTM 7.01b - Cost of Revenue TTM 4.44b) / Revenue TTM)
Gross Margin QoQ = 35.55% (prev 32.08%)
Tobins Q-Ratio = 1.04 (Enterprise Value 25.02b / Total Assets 24.01b)
Interest Expense / Debt = 1.21% (Interest Expense 50.0m / Debt 4.12b)
Taxrate = 23.88% (101.0m / 423.0m)
NOPAT = 1.70b (EBIT 2.23b * (1 - 23.88%))
Current Ratio = 1.02 (Total Current Assets 1.53b / Total Current Liabilities 1.49b)
Debt / Equity = 0.28 (Debt 4.12b / totalStockholderEquity, last quarter 14.72b)
Debt / EBITDA = 0.91 (Net Debt 4.02b / EBITDA 4.42b)
Debt / FCF = 2.78 (Net Debt 4.02b / FCF TTM 1.45b)
Total Stockholder Equity = 14.15b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.46% (Net Income 1.65b / Total Assets 24.01b)
RoE = 11.63% (Net Income TTM 1.65b / Total Stockholder Equity 14.15b)
RoCE = 12.51% (EBIT 2.23b / Capital Employed (Equity 14.15b + L.T.Debt 3.67b))
RoIC = 9.37% (NOPAT 1.70b / Invested Capital 18.13b)
WACC = 7.16% (E(21.00b)/V(25.12b) * Re(8.38%) + D(4.12b)/V(25.12b) * Rd(1.21%) * (1-Tc(0.24)))
Discount Rate = 8.38% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.58%
[DCF Debug] Terminal Value 81.04% ; FCFF base≈1.32b ; Y1≈1.29b ; Y5≈1.32b
Fair Price DCF = 31.33 (EV 27.88b - Net Debt 4.02b = Equity 23.86b / Shares 761.4m; r=7.16% [WACC]; 5y FCF grow -2.75% → 2.90% )
EPS Correlation: -74.47 | EPS CAGR: -55.38% | SUE: -4.0 | # QB: 0
Revenue Correlation: -47.62 | Revenue CAGR: -4.32% | SUE: 0.91 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.59 | Chg30d=-0.135 | Revisions Net=-8 | Analysts=17
EPS next Year (2026-12-31): EPS=2.21 | Chg30d=-0.389 | Revisions Net=-14 | Growth EPS=+2.9% | Growth Revenue=+1.8%